STOCK TITAN

State Street reports 6.4% Myriad Genetics (MYGN) stake in Schedule 13G

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Myriad Genetics, Inc. common stock as of 12/31/2025. State Street reports beneficial ownership of 5,966,567 shares, representing 6.4% of Myriad Genetics’ outstanding common stock.

The filing shows State Street has shared voting power over 5,683,556 shares and shared dispositive power over 5,966,567 shares, with no sole voting or dispositive power. State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Myriad Genetics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



STATE STREET CORPORATION
Signature:ELIZABETH SCHAEFER
Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:02/09/2026

FAQ

What stake in Myriad Genetics (MYGN) did State Street disclose?

State Street Corporation disclosed a 6.4% beneficial ownership stake in Myriad Genetics common stock. The filing reports ownership of 5,966,567 shares as of December 31, 2025, making State Street a significant institutional holder of the company’s shares.

How much voting and dispositive power does State Street have over MYGN shares?

State Street reports shared voting power over 5,683,556 shares and shared dispositive power over 5,966,567 shares of Myriad Genetics. It reports no sole voting power and no sole dispositive power, indicating decisions are made jointly through affiliated entities.

Is State Street’s MYGN stake intended to influence control of Myriad Genetics?

No. State Street certifies the securities were acquired and are held in the ordinary course of business and not for changing or influencing control of Myriad Genetics. The Schedule 13G indicates a passive investment rather than an activist or control-seeking position.

Which State Street affiliates are linked to the Myriad Genetics (MYGN) holdings?

The filing lists several affiliated investment advisers, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd. as related entities.

What type of SEC filing did State Street use for its MYGN ownership?

State Street used a Schedule 13G filing to report its Myriad Genetics ownership. Schedule 13G is typically used by institutional or passive investors who exceed 5% beneficial ownership but do not seek to change or influence the issuer’s control.

On what date was State Street’s Myriad Genetics ownership measured?

The beneficial ownership information in State Street’s Schedule 13G for Myriad Genetics is stated as of December 31, 2025. The 6.4% stake and related share counts reflect holdings on that specific measurement date.

Myriad Genetics

NASDAQ:MYGN

View MYGN Stock Overview

MYGN Rankings

MYGN Latest News

MYGN Latest SEC Filings

MYGN Stock Data

432.01M
88.59M
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
SALT LAKE CITY